1-7 of 7
Shengli Cai
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Population pharmacokinetics (popPK) and exposure-response (ER) analyses of lbl-034, a potent GPRC5D T cell engager in patients with relapsed/refractory multiple myeloma

Free
Bin Fan, Juanjuan Wu, Leijun Hu, John Yang, Chengtao Lu, Wenduo He, Ting Lv, Xiaoqiang Kang, Shengli Cai
Journal: Blood
Blood (2025) 146 (Supplement 1): 6824.
https://doi.org/10.1182/blood-2025-6824
Published: 2025
Journal Articles

A first-in-human, phase I/II, open-label, multicenter, dose escalation and expansion study of lbl-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma

Free
Xuelin Dou, Yuping Zhong, Wanhong Zhao, Ling Qin, Xin Du, Aijun Liao, Zhongjun Xia, Chunyan Sun, Songfu Jiang, Dongping Huang, Haitang Xie, Liangming Ma, Jishi Wang, Fengyan Jin, Guifang Ouyang, Yanhong Tong, Min Dong, Bing Xu, Wenduo He, Shengli Cai, Jin Lu
Journal: Blood
Blood (2025) 146 (Supplement 1): 91.
https://doi.org/10.1182/blood-2025-91
Published: 2025
Journal Articles

Lbl-076, a first-in-class GPRC5DxCD38xCD3 trispecific T cell engager (TCE) for the treatment of relapsed/refractory multiple myeloma

Free
Mi Ding, Jianming Sun, Tongjun Liu, Yurong Qin, Min Chen, Mi Ye, Guojin Wu, Jordan Zhu, Shengli Cai, Xiaoqiang Kang, Hong Ling, Xiao Huang
Journal: Blood
Blood (2025) 146 (Supplement 1): 3302.
https://doi.org/10.1182/blood-2025-3302
Published: 2025
Journal Articles

Pharmacokinetics, pharmacodynamics, and biomarkers of lbl-034, a GPRC5D-targeted T cell engager, in a first-in-human phase Ⅰ/Ⅱ study in relapsed/refractory multiple myeloma

Free
Bin Fan, Juanjuan Wu, Jin Lu, Xuelin Dou, Wenduo He, Chengtao Lu, Ting Lv, Yilan Mei, Xiaoqiang Kang, Shengli Cai
Journal: Blood
Blood (2025) 146 (Supplement 1): 4070.
https://doi.org/10.1182/blood-2025-4070
Published: 2025
Journal Articles

Proof of concept and mechanistic evaluation of lbl-034, a potent GPRC5D-targeting T cell engager with affinity-optimized, sterically engineered anti-CD3 arm, in a multiple myeloma xenograft mouse model

Free
Juanjuan Wu, Bin Fan, Wenduo He, Chengtao Lu, Yilan Mei, Xiaofan Hou, Xiaoqiang Kang, Shengli Cai
Journal: Blood
Blood (2025) 146 (Supplement 1): 2155.
https://doi.org/10.1182/blood-2025-2155
Published: 2025
Journal Articles

Lbl-034, a Highly Differentiated T-Cell Engaging Bispecific Antibody Targeting GPRC5D for the Treatment of Relapsed or Refractory Multiple Myeloma

Free
Baohui Wang, Xiao Huang, Jianming Sun, Yurong Qin, Hongyan Shang, Tingting Li, Guojin Wu, Min Chen, Hailin Wang, Peng Zhang, Duqing Jiang, Tongjun Liu, Mi Ye, Shengli Cai, Shoupeng Lai, Xiaoqiang Kang, Hong Ling
Journal: Blood
Blood (2023) 142 (Supplement 1): 4672.
https://doi.org/10.1182/blood-2023-181395
Published: 2023
Journal Articles

The Novel Human Double Minute (HDM)-2 Inhibitor DS-5272 Is Active Both Alone, and In Combination With Other Novel Agents, Against Multiple Myeloma

Free
Dongmin Gu, M.D., Ph.D., Hua Wang, Ph.D., Zhiqiang Wang, Ph.D., Richard E. Davis, M.D., Shengli Cai, M.D., Ph.D., Takahiko Seki, Ph.D., Archie Tse, M.D., Ph.D., Robert Z. Orlowski, M.D., Ph.D
Journal: Blood
Blood (2013) 122 (21): 1927.
https://doi.org/10.1182/blood.V122.21.1927.1927
Published: 2013